Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Conmed ( (CNMD) ) has shared an update.
On January 12, 2026, CONMED presented an investor deck at the J.P. Morgan Healthcare Conference that outlined preliminary 2026 financial guidance and highlighted its expectation for mid‑term revenue growth of roughly 4% to 9% at the company level, underpinned by 4% to 8% growth in orthopedics and 5% to 11% in general surgery. The materials emphasized the firm’s track record of consistent revenue and adjusted EPS expansion, driven by high‑growth platforms such as the AirSeal insufflation system, Buffalo Filter smoke evacuation products, and BioBrace reinforced bioinductive implants, all positioned in large and growing markets with clinical differentiation and regulatory or legislative tailwinds, signaling management’s confidence in sustained long‑term growth and reinforcing CONMED’s competitive positioning in minimally invasive surgery and sports medicine.
The most recent analyst rating on (CNMD) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.
Spark’s Take on CNMD Stock
According to Spark, TipRanks’ AI Analyst, CNMD is a Neutral.
Conmed’s overall stock score reflects strong financial performance and strategic initiatives aimed at long-term growth. However, bearish technical indicators and challenges in maintaining profit margins weigh on the score. The strategic shift in capital allocation and positive corporate governance changes provide additional support.
To see Spark’s full report on CNMD stock, click here.
More about Conmed
CONMED Corporation is a global medical technology company focused on orthopedics and general surgery, with a portfolio that spans sports medicine, orthopedic capital equipment and disposables, foot and ankle solutions, advanced insufflation and surgical smoke evacuation systems, and surgical instruments. The company generates the majority of its revenue from single-use products, operates across domestic and international markets, and targets mid‑single‑ to double‑digit growth in key segments such as sports medicine, foot and ankle, and its AirSeal, Buffalo Filter and BioBrace platforms.
Average Trading Volume: 532,271
Technical Sentiment Signal: Sell
Current Market Cap: $1.37B
For a thorough assessment of CNMD stock, go to TipRanks’ Stock Analysis page.